Literature DB >> 22912552

Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome.

Philippe Ducrotté1, Prabha Sawant, Venkataraman Jayanthi.   

Abstract

AIM: To assess the symptomatic efficacy of Lactobacillus plantarum 299v (L. plantarum 299v) (DSM 9843) for the relief of abdominal symptoms in a large subset of irritable bowel syndrome (IBS) patients fulfilling the Rome III criteria.
METHODS: In this double blind, placebo-controlled, parallel-designed study, subjects were randomized to daily receive either one capsule of L. plantarum 299v (DSM 9843) or placebo for 4 wk. Frequency and intensity of abdominal pain, bloating and feeling of incomplete rectal emptying were assessed weekly on a visual analogue scale while stool frequency was calculated.
RESULTS: Two hundred and fourteen IBS patients were recruited. After 4 wk, both pain severity (0.68 + 0.53 vs 0.92 + 0.57, P < 0.05) and daily frequency (1.01 + 0.77 vs 1.71 + 0.93, P < 0.05) were lower with L. plantarum 299v (DSM 9843) than with placebo. Similar results were obtained for bloating. At week 4, 78.1 % of the patients scored the L. plantarum 299v (DSM 9843) symptomatic effect as excellent or good vs only 8.1 % for placebo (P < 0.01).
CONCLUSION: A 4-wk treatment with L. plantarum 299v (DSM 9843) provided effective symptom relief, particularly of abdominal pain and bloating, in IBS patients fulfilling the Rome III criteria.

Entities:  

Keywords:  Abdominal pain; Clinical trial; Irritable bowel syndrome; Lactobacillus plantarum 299v; Probiotics

Mesh:

Year:  2012        PMID: 22912552      PMCID: PMC3419998          DOI: 10.3748/wjg.v18.i30.4012

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  27 in total

1.  British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome.

Authors:  J Jones; J Boorman; P Cann; A Forbes; J Gomborone; K Heaton; P Hungin; D Kumar; G Libby; R Spiller; N Read; D Silk; P Whorwell
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

Review 2.  An evidence-based position statement on the management of irritable bowel syndrome.

Authors:  Lawrence J Brandt; William D Chey; Amy E Foxx-Orenstein; Lawrence R Schiller; Philip S Schoenfeld; Brennan M Spiegel; Nicholas J Talley; Eamonn M M Quigley
Journal:  Am J Gastroenterol       Date:  2009-01       Impact factor: 10.864

3.  A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome.

Authors:  K Niedzielin; H Kordecki; B Birkenfeld
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-10       Impact factor: 2.566

4.  Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans.

Authors:  C N Jacobsen; V Rosenfeldt Nielsen; A E Hayford; P L Møller; K F Michaelsen; A Paerregaard; B Sandström; M Tvede; M Jakobsen
Journal:  Appl Environ Microbiol       Date:  1999-11       Impact factor: 4.792

5.  Irritable bowel syndrome in a rural community in Bangladesh: prevalence, symptoms pattern, and health care seeking behavior.

Authors:  M A Masud; M Hasan; A K Khan
Journal:  Am J Gastroenterol       Date:  2001-05       Impact factor: 10.864

6.  Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome.

Authors:  Mirjana Rajilić-Stojanović; Elena Biagi; Hans G H J Heilig; Kajsa Kajander; Riina A Kekkonen; Sebastian Tims; Willem M de Vos
Journal:  Gastroenterology       Date:  2011-08-05       Impact factor: 22.682

7.  Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome.

Authors:  S Nobaek; M L Johansson; G Molin; S Ahrné; B Jeppsson
Journal:  Am J Gastroenterol       Date:  2000-05       Impact factor: 10.864

8.  Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome.

Authors:  S Sen; M M Mullan; T J Parker; J T Woolner; S A Tarry; J O Hunter
Journal:  Dig Dis Sci       Date:  2002-11       Impact factor: 3.199

9.  Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome.

Authors:  A C Ford; P Moayyedi
Journal:  Aliment Pharmacol Ther       Date:  2010-04-16       Impact factor: 8.171

Review 10.  Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed.

Authors:  Kok-Ann Gwee; Ching-Liang Lu; Uday Chand Ghoshal
Journal:  J Gastroenterol Hepatol       Date:  2009-10       Impact factor: 4.029

View more
  68 in total

Review 1.  Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Authors:  Eleonora Distrutti; Lorenzo Monaldi; Patrizia Ricci; Stefano Fiorucci
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

Review 2.  Current and emerging pharmacotherapeutic options for irritable bowel syndrome.

Authors:  Jose L Barboza; Nicholas J Talley; Baharak Moshiree
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

Review 3.  Lactobacillus plantarum and Its Probiotic and Food Potentialities.

Authors:  Hamza Ait Seddik; Farida Bendali; Frédérique Gancel; Ismail Fliss; Giuseppe Spano; Djamel Drider
Journal:  Probiotics Antimicrob Proteins       Date:  2017-06       Impact factor: 4.609

Review 4.  Probiotics, prebiotics and the gastrointestinal tract in health and disease.

Authors:  Luis Vitetta; David Briskey; Hollie Alford; Sean Hall; Samantha Coulson
Journal:  Inflammopharmacology       Date:  2014-03-16       Impact factor: 4.473

5.  Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome: a randomized, double-blind, placebo-controlled, dose-finding trial.

Authors:  Ji Yeon Kim; Yeo Jin Park; Hyo Jin Lee; Min Young Park; Oran Kwon
Journal:  Food Sci Biotechnol       Date:  2017-12-12       Impact factor: 2.391

Review 6.  Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate.

Authors:  Antonella Gallo; Giovanna Passaro; Antonio Gasbarrini; Raffaele Landolfi; Massimo Montalto
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

Review 7.  Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.

Authors:  Tina Didari; Shilan Mozaffari; Shekoufeh Nikfar; Mohammad Abdollahi
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

Review 8.  Quantitative Risk-Benefit Analysis of Probiotic Use for Irritable Bowel Syndrome and Inflammatory Bowel Disease.

Authors:  William E Bennett
Journal:  Drug Saf       Date:  2016-04       Impact factor: 5.606

Review 9.  Microscopic colitis-microbiome, barrier function and associated diseases.

Authors:  Saskia van Hemert; Karolina Skonieczna-Żydecka; Igor Loniewski; Piotr Szredzki; Wojciech Marlicz
Journal:  Ann Transl Med       Date:  2018-02

Review 10.  Close association between intestinal microbiota and irritable bowel syndrome.

Authors:  W-T Fan; C Ding; N-N Xu; S Zong; P Ma; B Gu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-08-07       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.